Literature DB >> 24075805

Propofol for benzodiazepine-refractory alcohol withdrawal in a non-mechanically ventilated patient.

Darrel W Hughes1, Elizabeth Vanwert2, Lauren Lepori3, Bruce D Adams3.   

Abstract

Long-term alcohol use confers neurochemical changes in response to alcohol's exogenous inhibitory effects. Downregulation and decreased sensitivity of γ-aminobutyric acid receptors render benzodiazepines less effective at controlling psychomotor agitation. Propofol has been reported to have successfully relieved alcohol withdrawal syndrome (AWS) symptoms in part because of activation of γ-aminobutyric acid channels in combination with antagonism of excitatory amino acids such as N-methyl-D-aspartate. Successful use of propofol in refractory AWS in patients with endotracheal intubation and mechanical ventilation has been reported. We present a case of resolution of AWS symptoms in a benzodiazepine-refractory, nonintubated, non-mechanically ventilated alcohol withdrawal patient with low-dose, continuous-infusion propofol.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24075805     DOI: 10.1016/j.ajem.2013.08.044

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  3 in total

Review 1.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

Review 2.  Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence.

Authors:  María Luisa Gutiérrez García; Sara Blasco-Algora; Conrado M Fernández-Rodríguez
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

3.  Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal.

Authors:  Riley J Lizotte; John A Kappes; Billie J Bartel; Katie M Hayes; Veronica L Lesselyoung
Journal:  Clin Pharmacol       Date:  2014-10-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.